Cargando…

Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)

Background: Phenprocoumon has been used as an oral anticoagulant in patients with thromboembolic disease for more than 40 years. So far its pharmacokinetics have not been analyzed in emergency situations. Methods: Phenprocoumon-treated patients with major bleeding or urgent surgery were included in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindhoff-Last, Edelgard, Birschmann, Ingvild, Bidenharn, Antonia J., Kuhn, Joachim, Lindau, Simone, Konstantinides, Stavros, Grottke, Oliver, Nowak-Göttl, Ulrike, Lucks, Jessica, Zydek, Barbara, von Heymann, Christian, Sümnig, Ariane, Beyer-Westendorf, Jan, Schellong, Sebastian, Meybohm, Patrick, Greinacher, Andreas, Herrmann, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692621/
https://www.ncbi.nlm.nih.gov/pubmed/36422567
http://dx.doi.org/10.3390/ph15111437
_version_ 1784837313114669056
author Lindhoff-Last, Edelgard
Birschmann, Ingvild
Bidenharn, Antonia J.
Kuhn, Joachim
Lindau, Simone
Konstantinides, Stavros
Grottke, Oliver
Nowak-Göttl, Ulrike
Lucks, Jessica
Zydek, Barbara
von Heymann, Christian
Sümnig, Ariane
Beyer-Westendorf, Jan
Schellong, Sebastian
Meybohm, Patrick
Greinacher, Andreas
Herrmann, Eva
author_facet Lindhoff-Last, Edelgard
Birschmann, Ingvild
Bidenharn, Antonia J.
Kuhn, Joachim
Lindau, Simone
Konstantinides, Stavros
Grottke, Oliver
Nowak-Göttl, Ulrike
Lucks, Jessica
Zydek, Barbara
von Heymann, Christian
Sümnig, Ariane
Beyer-Westendorf, Jan
Schellong, Sebastian
Meybohm, Patrick
Greinacher, Andreas
Herrmann, Eva
author_sort Lindhoff-Last, Edelgard
collection PubMed
description Background: Phenprocoumon has been used as an oral anticoagulant in patients with thromboembolic disease for more than 40 years. So far its pharmacokinetics have not been analyzed in emergency situations. Methods: Phenprocoumon-treated patients with major bleeding or urgent surgery were included in a prospective, observational registry. Phenprocoumon drug concentrations were analyzed in samples, collected as part of routine care using ultraperformance liquid chromatography tandem mass spectrometry. Moreover, anticoagulant intensity and drug half-life (t1/2) were calculated. Results: 115 patients were included. Phenprocoumon levels declined over time with a half-life of 5.27 and 5.29 days in patients with major bleedings (n = 82) and with urgent surgery (n = 33). Baseline phenprocoumon levels were 2.2 times higher in the bleeding group compared to the surgery group (1.92 vs. 0.87 ng/mL, p < 0.0001). International normalized ratio (INR) values decreased rapidly during the first 24 h. In 27.6% of patients a rebound of INR (recurrent increase > 1.5) was observed which was associated with significantly increased bleeding rates (22% vs. 4.2% in patients with or without INR rebound, p = 0.012). Conclusions: In emergency situations, the long half-life of phenprocoumon may cause INR rebound and associated recurrent bleedings. Optimal management may need to include repeated vitamin K supplementation over days.
format Online
Article
Text
id pubmed-9692621
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96926212022-11-26 Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry) Lindhoff-Last, Edelgard Birschmann, Ingvild Bidenharn, Antonia J. Kuhn, Joachim Lindau, Simone Konstantinides, Stavros Grottke, Oliver Nowak-Göttl, Ulrike Lucks, Jessica Zydek, Barbara von Heymann, Christian Sümnig, Ariane Beyer-Westendorf, Jan Schellong, Sebastian Meybohm, Patrick Greinacher, Andreas Herrmann, Eva Pharmaceuticals (Basel) Article Background: Phenprocoumon has been used as an oral anticoagulant in patients with thromboembolic disease for more than 40 years. So far its pharmacokinetics have not been analyzed in emergency situations. Methods: Phenprocoumon-treated patients with major bleeding or urgent surgery were included in a prospective, observational registry. Phenprocoumon drug concentrations were analyzed in samples, collected as part of routine care using ultraperformance liquid chromatography tandem mass spectrometry. Moreover, anticoagulant intensity and drug half-life (t1/2) were calculated. Results: 115 patients were included. Phenprocoumon levels declined over time with a half-life of 5.27 and 5.29 days in patients with major bleedings (n = 82) and with urgent surgery (n = 33). Baseline phenprocoumon levels were 2.2 times higher in the bleeding group compared to the surgery group (1.92 vs. 0.87 ng/mL, p < 0.0001). International normalized ratio (INR) values decreased rapidly during the first 24 h. In 27.6% of patients a rebound of INR (recurrent increase > 1.5) was observed which was associated with significantly increased bleeding rates (22% vs. 4.2% in patients with or without INR rebound, p = 0.012). Conclusions: In emergency situations, the long half-life of phenprocoumon may cause INR rebound and associated recurrent bleedings. Optimal management may need to include repeated vitamin K supplementation over days. MDPI 2022-11-19 /pmc/articles/PMC9692621/ /pubmed/36422567 http://dx.doi.org/10.3390/ph15111437 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lindhoff-Last, Edelgard
Birschmann, Ingvild
Bidenharn, Antonia J.
Kuhn, Joachim
Lindau, Simone
Konstantinides, Stavros
Grottke, Oliver
Nowak-Göttl, Ulrike
Lucks, Jessica
Zydek, Barbara
von Heymann, Christian
Sümnig, Ariane
Beyer-Westendorf, Jan
Schellong, Sebastian
Meybohm, Patrick
Greinacher, Andreas
Herrmann, Eva
Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
title Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
title_full Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
title_fullStr Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
title_full_unstemmed Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
title_short Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
title_sort pharmacokinetics of phenprocoumon in emergency situations–results of the prospective observational radoa-registry (reversal agent use in patients treated with direct oral anticoagulants or vitamin k antagonists registry)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692621/
https://www.ncbi.nlm.nih.gov/pubmed/36422567
http://dx.doi.org/10.3390/ph15111437
work_keys_str_mv AT lindhofflastedelgard pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT birschmanningvild pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT bidenharnantoniaj pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT kuhnjoachim pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT lindausimone pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT konstantinidesstavros pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT grottkeoliver pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT nowakgottlulrike pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT lucksjessica pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT zydekbarbara pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT vonheymannchristian pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT sumnigariane pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT beyerwestendorfjan pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT schellongsebastian pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT meybohmpatrick pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT greinacherandreas pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry
AT herrmanneva pharmacokineticsofphenprocoumoninemergencysituationsresultsoftheprospectiveobservationalradoaregistryreversalagentuseinpatientstreatedwithdirectoralanticoagulantsorvitaminkantagonistsregistry